Mustbio's next-generation immuno-oncology candidate, MB7 (tri-specific fusion protein comprising αPD-1/αVEGF/IL-21v), has been selected for the 2025 "Cancer Therapeutic Efficacy Evaluation/Consulting Service" program, organized by the Asan Preclinical Evaluation Center for cancer therapeutiX (APEX) at Asan Medical Center and supported by the Ministry of Health and Welfare of Korea.

This government-supported program aims to objectively evaluate the efficacy of promising anticancer drug candidates and provides approximately KRW 100 million worth of in vivo efficacy studies over one year.

Through this project, Mustbio aims to validate the superior anti-tumor efficacy of MB7 in a rigorous preclinical setting and strengthen its position for future clinical development and global competitiveness.